Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 28;44(10):116440.
doi: 10.1016/j.celrep.2025.116440. Epub 2025 Oct 14.

Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants

Affiliations
Free article

Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants

Ian A Mellis et al. Cell Rep. .
Free article

Erratum in

Abstract

SARS-CoV-2 continues to evolve, causing waves of infections. It is critical to understand the features of the virus that explain its growth advantages. Recently, SARS-CoV-2 Omicron JN.1 subvariants KP.3.1.1 and XEC were outcompeted by LP.8.1 and LP.8.1.1. Other subvariants, including LF.7.2.1 and MC.10.1, were also under monitoring. Subsequently, NB.1.8.1 and XFG became dominant. We found that serum neutralizing antibody titers against LP.8.1, LP.8.1.1, LF.7, LF.7.2.1, and MC.10.1 were similar to XEC in 40 adults, including KP.2 monovalent mRNA vaccine recipients. NB.1.8.1 and XFG were more evasive of serum neutralization than LP.8.1.1. Neutralization by 12 monoclonal antibodies (mAbs) revealed that LP.8.1 and XFG, MC.10.1 and NB.1.8.1, and LF.7.2.1 evade different mAb classes. Lastly, the receptor-binding affinity of LP.8.1 was the highest among the tested viruses. Unlike most prior SARS-CoV-2 sublineage evolutionary trajectories, receptor-binding affinity better explained the rise of LP.8.1, while expansion of NB.1.8.1 and XFG appears correlated with enhanced antibody evasion.

Keywords: COVID-19; CP: Immunology; CP: Microbiology; KP.2; LP.8.1; NB.1.8.1; SARS-CoV-2; XFG; mRNA vaccines; neutralizing antibodies.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests D.D.H. co-founded TaiMed Biologics and RenBio, and he serves as a consultant for WuXi Biologics and Brii Biosciences and is a board director at Vicarious Surgical. A.G. served as a member of the scientific advisory board for Janssen Pharmaceuticals and has consulted and serves on a scientific advisory board for Sanofi Pasteur.

MeSH terms

Supplementary concepts

LinkOut - more resources